[go: up one dir, main page]

BRPI0511753A - formulação de irinotecano e respectiva composição farmacêutica - Google Patents

formulação de irinotecano e respectiva composição farmacêutica

Info

Publication number
BRPI0511753A
BRPI0511753A BRPI0511753-4A BRPI0511753A BRPI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A
Authority
BR
Brazil
Prior art keywords
irinotecan
formulation
mol
liposome
pharmaceutical composition
Prior art date
Application number
BRPI0511753-4A
Other languages
English (en)
Inventor
Keisuke Yoshino
Shigenori Nozawa
Masashi Isozaki
Seigo Sawada
Ikuo Kato
Takeshi Matsuzaki
Original Assignee
Terumo Corp
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp, Yakult Honsha Kk filed Critical Terumo Corp
Publication of BRPI0511753A publication Critical patent/BRPI0511753A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO DE IRINOTECANO E RESPECTIVA COMPOSIçãO FARMACêUTICA. A presente invenção refere-se a uma formulação de irinotecano capaz de suportar o irinotecano e/ou um sal do mesmo em um veículo de vesícula fechada, em uma alta concentração, e existindo no sangue por um período longo de tempo pela retentividade dramaticamente aperfeiçoada no sangue, comparada a uma formulação de lipossomo de irinotecano convencionalmente conhecida. Ou seja, uma formulação de irinotecano que inclui uma vesícula fechada formada por uma membrana lipídica, em que o irinotecano e/ou um sal do mesmo é encapsulado em uma concentração de pelo menos 0,07 mol/mol (mol de fármaco/mol de lipídios totais da membrana). Há um gradiente iónico entre uma fase aquosa interna e uma fase aquosa externa na formulação de irinotecano. A vesícula fechada é preferivelmente o lipossomo, em que somente a superfície externa do lipossomo é preferivelmente modificada com um agente modificador da superfície contendo um polímero hidrofílico.
BRPI0511753-4A 2004-06-01 2005-05-31 formulação de irinotecano e respectiva composição farmacêutica BRPI0511753A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01
PCT/JP2005/009953 WO2005117878A1 (ja) 2004-06-01 2005-05-31 イリノテカン製剤

Publications (1)

Publication Number Publication Date
BRPI0511753A true BRPI0511753A (pt) 2008-01-02

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511753-4A BRPI0511753A (pt) 2004-06-01 2005-05-31 formulação de irinotecano e respectiva composição farmacêutica

Country Status (24)

Country Link
US (1) US7846473B2 (pt)
EP (1) EP1752150B1 (pt)
JP (1) JP4885715B2 (pt)
KR (1) KR100889139B1 (pt)
CN (1) CN1960729B (pt)
AP (1) AP2255A (pt)
AR (1) AR049137A1 (pt)
AU (1) AU2005249314B2 (pt)
BR (1) BRPI0511753A (pt)
CA (1) CA2567857C (pt)
CR (1) CR8768A (pt)
EA (1) EA011612B1 (pt)
EC (1) ECSP067041A (pt)
ES (1) ES2594621T3 (pt)
GE (1) GEP20094620B (pt)
IL (1) IL179558A0 (pt)
MX (1) MXPA06013874A (pt)
NO (1) NO20066074L (pt)
NZ (1) NZ551748A (pt)
TN (1) TNSN06395A1 (pt)
TW (1) TWI362931B (pt)
UA (1) UA85099C2 (pt)
WO (1) WO2005117878A1 (pt)
ZA (1) ZA200610204B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566007C (en) 2004-05-03 2013-09-24 Hermes Biosciences, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
PL2508170T3 (pl) * 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
WO2013067449A1 (en) 2011-11-03 2013-05-10 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014039504A1 (en) * 2012-09-04 2014-03-13 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
KR20180037210A (ko) 2015-08-20 2018-04-11 입센 바이오팜 리미티드 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법
TW202126293A (zh) 2015-08-21 2021-07-16 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
JP6941606B2 (ja) 2015-10-16 2021-09-29 イプセン バイオファーム リミティド 安定化カンプトテシン医薬組成物
SG11201903615WA (en) * 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CN117547535A (zh) 2021-10-15 2024-02-13 昆山新蕴达生物科技有限公司 包含抗肿瘤药物的组合物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
IL142573A0 (en) * 1998-09-16 2002-03-10 Alza Corp Liposome-entrapped topoisomerase inhibitors
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
ATE430556T1 (de) 1999-06-25 2009-05-15 Terumo Corp Liposome
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU2001270413A1 (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corporation Improved liposomal camptothecins and uses thereof
DE60216305T2 (de) 2001-10-03 2007-07-05 Celator Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen
DE60237162D1 (de) 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
CA2467064C (en) * 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
AU2002340670A1 (en) * 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
EP1608338A1 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CA2566007C (en) * 2004-05-03 2013-09-24 Hermes Biosciences, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars

Also Published As

Publication number Publication date
AP2006003837A0 (en) 2006-12-31
TW200600095A (en) 2006-01-01
ES2594621T3 (es) 2016-12-21
JPWO2005117878A1 (ja) 2008-04-03
AU2005249314A1 (en) 2005-12-15
EP1752150A1 (en) 2007-02-14
AR049137A1 (es) 2006-06-28
EA200602246A1 (ru) 2007-04-27
KR20070037440A (ko) 2007-04-04
ECSP067041A (es) 2006-12-29
TWI362931B (en) 2012-05-01
CA2567857A1 (en) 2005-12-15
AP2255A (en) 2011-07-21
EP1752150B1 (en) 2016-08-31
AU2005249314B2 (en) 2008-09-11
CN1960729B (zh) 2012-04-11
GEP20094620B (en) 2009-02-25
TNSN06395A1 (en) 2008-02-22
MXPA06013874A (es) 2007-04-25
NO20066074L (no) 2007-02-28
WO2005117878A1 (ja) 2005-12-15
CN1960729A (zh) 2007-05-09
US7846473B2 (en) 2010-12-07
JP4885715B2 (ja) 2012-02-29
KR100889139B1 (ko) 2009-03-17
CA2567857C (en) 2009-12-22
IL179558A0 (en) 2007-07-04
EA011612B1 (ru) 2009-04-28
UA85099C2 (en) 2008-12-25
US20080069868A1 (en) 2008-03-20
NZ551748A (en) 2010-02-26
CR8768A (es) 2007-08-28
ZA200610204B (en) 2008-01-30
EP1752150A4 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
BRPI0511753A (pt) formulação de irinotecano e respectiva composição farmacêutica
Müller et al. Targeting of the pro‐apoptotic VDAC‐like porin (PorB) of Neisseria gonorrhoeae to mitochondria of infected cells
Alarcón et al. Ion channel formation by Alzheimer's disease amyloid β-peptide (Aβ40) in unilamellar liposomes is determined by anionic phospholipids
Van Rooijen et al. Membrane binding of oligomeric α-synuclein depends on bilayer charge and packing
Mingeot‐Leclercq et al. Molecular parameters involved in aminoglycoside nephrotoxicity
Ferrada et al. Dehydroascorbic acid sensitizes cancer cells to system xc-inhibition-induced ferroptosis by promoting lipid droplet peroxidation
Wang et al. Effects of PEO− PPO− PEO triblock copolymers on phospholipid membrane integrity under osmotic stress
BRPI0416650A (pt) composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase
Jaremko et al. Accelerated hemolysis and neurotoxicity in neuron‐glia‐blood clot co‐cultures
Barhwal et al. Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: complementary roles of L-type calcium channel and NMDA receptors
Fabrizio et al. In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of potassium sorbate
Romero et al. Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes
Albalak et al. Effects of submicellar bile salt concentrations on biological membrane permeability to low molecular weight non-ionic solutes
CN109260155A (zh) 伊立替康脂质体制剂及其制备与应用
Bolard et al. Interaction of the anti-Candida amphotericin B (and other polyene antibiotics) with lipids
Sulaiman et al. SapC-DOPS nanovesicles induce Smac-and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas
Bartkowiak et al. Study of mucin interaction with model phospholipid membrane at the air–water interface
Sadzuka et al. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy
Arvind et al. Mouse Apolipoprotein L9 is a phosphatidylethanolamine-binding protein
Vittori et al. Erythrocyte: programmed cell death
McCaig Membrane surface charge, phospholipids, and protein localization
Belkherroubi-Sari et al. New strategy for enhancing the therapeutic index of Fungizone®
ES2991863T3 (es) Nanoliposomas para la administración sostenida de tacrolimus para el tratamiento de enfermedades oculares del segmento anterior
IT202000027155A1 (it) Formulazione a base di poliesametilene biguanide per il trattamento della cheratite da acanthamoeba
Brenza et al. Interaction of Ca2+ with cardiolipin-containing liposomes and its inhibition by adriamycin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.